

**Asia Pacific Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 210 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The glycomic therapeutics market in Asia Pacific is expected to grow from US\$ 12.95 billion in 2022 to US\$ 34.59 billion by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028.

#### Wide Applications of Glycomics in Therapeutics to Provide Lucrative Opportunities for Market Growth

Glycomics is a novel method for creating medicines. It draws on the knowledge that glycans serve as the primary means of altering numerous molecules in biological systems. This alteration provides those molecules with their complete, functional form. Glycans are found in most top-selling biologics and half of the therapeutic proteins, including antibodies against COVID-19. Glycans of these proteins have been tailored to improve their effectiveness, lower the dosages required, and lessen negative effects. For instance, understanding the biological functions of glycans has led to their inclusion as essential ingredients in medications for the treatment of diabetes, the prevention of blood clotting, and the improvement of in vitro fertilization. Changes in the glycans on a microbe's surface are frequently connected to the microorganisms' resistance to popular medications. This property is used for detecting particular glycans in infection samples, disabling the protective biofilms formed by the infecting bacteria, and weakening the glycan-rich cell walls of microorganisms. More than 130 uncommon genetic illnesses, many of which are fatal in childhood, are brought on by errors. Understanding the glycans responsible for a few of these problems has helped develop therapies. Since glycans can play a crucial role in studying attacks of bacteria and viruses on the immune systems of humans, they are employed in vaccinations. Additionally, recent research on SARS-CoV-2, which causes COVID-19, has shown infection pathways that depend on the virus's usage of human glycans. Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomics in various therapeutic areas would propel the demand for these techniques in the coming years. Nonetheless, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomics therapeutics market during the forecast period.

#### Market Overview

Asia Pacific (APAC) is the fastest-growing market for glycomic therapeutics. The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is likely to account for ~11.89% share of the global glycomic therapeutics market in 2022 owing to the improving government support in countries, collaboration of research organizations, rising glycomics research institutes, and advancing healthcare infrastructure. Therefore, the region offers several opportunities for the glycomic therapeutics market players to grow during the forecast period.

#### Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 (US\$ Billion)

#### Asia Pacific Glycomic Therapeutics Market Segmentation

The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Asia Pacific glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

(ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.

BioMarinPharmaceuticalInc.;GenzymeCorporation(Sanofi);BayerAG;Alzheon,Inc.;GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in Asia Pacific.

## **Table of Contents:**

### **TABLE OF CONTENTS**

1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 Asia Pacific Glycomic Therapeutics Market - By Class
    - 1.3.2 Asia Pacific Glycomic Therapeutics Market - By Structures
    - 1.3.3 Asia Pacific Glycomic Therapeutics Market - By Indications
    - 1.3.4 Asia Pacific Glycomic Therapeutics Market - By Mode of Action
    - 1.3.5 Asia Pacific Glycomic Therapeutics Market - By Country
2. Asia Pacific Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. Asia Pacific Glycomic Therapeutics Market - Market Landscape
  - 4.1 Overview
  - 4.2 PEST Analysis
    - 4.2.1 Asia Pacific - PEST Analysis
  - 4.3 Expert Opinion
5. Asia Pacific Glycomic Therapeutics Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
    - 5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
  - 5.2 Market Restraints
    - 5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
  - 5.3 Market Opportunities
    - 5.3.1 Wide Applications of Glycomics in Therapeutics
  - 5.4 Future Trends
    - 5.4.1 New Tools in Glycomics Research
  - 5.5 Impact Analysis
6. Glycomic Therapeutics Market- Asia Pacific Analysis
  - 6.1 Asia Pacific Glycomic Therapeutics Market Revenue Forecast and Analysis
    - 6.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US\$ Million)
7. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
  - 7.1 Overview
  - 7.2 Asia Pacific Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
    - 7.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.3 Isolated
  - 7.3.1 Overview
  - 7.3.2 Asia Pacific Isolated Revenue and Forecast to 2028 (US\$ Million)
- 7.4 Synthetic
  - 7.4.1 Overview
  - 7.4.2 Asia Pacific Synthetic - Revenue and Forecast to 2028 (US\$ Million)
- 8. Asia Pacific Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
  - 8.1 Overview
  - 8.2 Asia Pacific Glycomics Market, By Indication 2022 & 2028 (%)
    - 8.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
  - 8.3 Thrombosis and Chemoprophylaxis
    - 8.3.1 Overview
    - 8.3.2 Asia Pacific Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US\$ Million)
  - 8.4 Anaemia
    - 8.4.1 Overview
    - 8.4.2 Asia Pacific Anaemia Revenue and Forecast to 2028 (US\$ Million)
  - 8.5 Anti-adhesive and Anti-inflammatory
    - 8.5.1 Overview
    - 8.5.2 Asia Pacific Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US\$ Million)
  - 8.6 Cataract
    - 8.6.1 Overview
    - 8.6.2 Asia Pacific Cataract Revenue and Forecast to 2028 (US\$ Million)
  - 8.7 Gaucher's diseases
    - 8.7.1 Overview
    - 8.7.2 Asia Pacific Gaucher's diseases Revenue and Forecast to 2028 (US\$ Million)
  - 8.8 MPS-1 & IV
    - 8.8.1 Overview
    - 8.8.2 Asia Pacific MPS-1 & IV Revenue and Forecast to 2028 (US\$ Million)
  - 8.9 Cancer
    - 8.9.1 Overview
    - 8.9.2 Asia Pacific Cancer Revenue and Forecast to 2028 (US\$ Million)
  - 8.10 Alzheimer's
    - 8.10.1 Overview
    - 8.10.2 Asia Pacific Alzheimer's Revenue and Forecast to 2028 (US\$ Million)
  - 8.11 Influenza Type A and B
    - 8.11.1 Overview
    - 8.11.2 Asia Pacific Influenza Type A and B Revenue and Forecast to 2028 (US\$ Million)
  - 8.12 Others
    - 8.12.1 Overview
    - 8.12.2 Asia Pacific Others Revenue and Forecast to 2028 (US\$ Million)
- 9. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
  - 9.1 Overview
  - 9.2 Asia Pacific Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
    - 9.2.1 Asia Pacific: Glycomic Therapeutics Market, by Structures, 2019-2028 (US\$ Million)
      - 9.2.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
      - 9.2.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.2.1.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)

9.2.1.4 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 Asia Pacific Glycoproteins - Market Revenue and Forecast to 2028 (US\$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 Asia Pacific Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US\$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.3.2 Asia Pacific Zanamivir - Market Revenue and Forecast to 2028 (US\$ Million)

9.4.4 Oseltamivir

9.4.4.1 Overview

9.4.4.2 Asia Pacific Oseltamivir - Market Revenue and Forecast to 2028 (US\$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 Asia Pacific Proteoglycans - Market Revenue and Forecast to 2028 (US\$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 Asia Pacific Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US\$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 Asia Pacific Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US\$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 Asia Pacific Heparin - Market Revenue and Forecast to 2028 (US\$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 Asia Pacific Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US\$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 Asia Pacific Laronidase - Market Revenue and Forecast to 2028 (US\$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 Asia Pacific Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US\$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 Asia Pacific Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US\$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US\$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 Asia Pacific Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US\$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.8.3.2 Asia Pacific Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US\$ Million)
- 9.8.3.3 Agalsidase (Fabrazyme)
  - 9.8.3.3.1 Overview
  - 9.8.3.3.2 Asia Pacific Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
  - 9.8.3.4.1 Overview
  - 9.8.3.4.2 Asia Pacific N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.8.4 Others
  - 9.8.4.1 Overview
  - 9.8.4.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.9 Others
  - 9.9.1 Overview
  - 9.9.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.3 Acarbose
    - 9.9.3.1 Overview
    - 9.9.3.2 Asia Pacific Acarbose - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.3.3 Alglucosidase Alfa (Myozyme)
    - 9.9.3.3.1 Overview
    - 9.9.3.3.2 Asia Pacific Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.3.4 Allosamidin
    - 9.9.3.4.1 Overview
    - 9.9.3.4.2 Asia Pacific Allosamidin - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.4 Others
    - 9.9.4.1 Overview
    - 9.9.4.2 Asia Pacific Others - Market Revenue and Forecast to 2028 (US\$ Million)
- 10. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
  - 10.1 Overview
  - 10.2 Asia Pacific Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
    - 10.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
  - 10.3 Inhibits Neuraminidase
    - 10.3.1 Overview
    - 10.3.2 Asia Pacific Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US\$ Million)
  - 10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
    - 10.4.1 Overview
    - 10.4.2 Asia Pacific Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US\$ Million)
  - 10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
    - 10.5.1 Overview
    - 10.5.2 Asia Pacific Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US\$ Million)
  - 10.6 Tissue Plasminogen Activator
    - 10.6.1 Overview
    - 10.6.2 Asia Pacific Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US\$ Million)
  - 10.7 Inhibits Glucosylceramide Synthase
    - 10.7.1 Overview
    - 10.7.2 Asia Pacific Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US\$ Million)
  - 10.8 Interleukin 1 And 2 And 3
    - 10.8.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.8.2 Asia Pacific Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.9 Beta And Gamma Interferons
  - 10.9.1 Overview
  - 10.9.2 Asia Pacific Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US\$ Million)
- 10.10 Others
  - 10.10.1 Overview
  - 10.10.2 Asia Pacific Others- Market Revenue And Forecasts To 2028 (US\$ Million)
- 11. Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
  - 11.1 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts To 2028
    - 11.1.1 Overview
      - 11.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)
        - 11.1.2.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
          - 11.1.2.1.1 Overview
            - 11.1.2.1.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
              - 11.1.2.1.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
                - 11.1.2.1.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US\$ Million)
                  - 11.1.2.1.4.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
                    - 11.1.2.1.4.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
                    - 11.1.2.1.4.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
                    - 11.1.2.1.4.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
                  - 11.1.2.1.5 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
                  - 11.1.2.1.6 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
                - 11.1.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
                  - 11.1.2.2.1 Overview
                    - 11.1.2.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
                      - 11.1.2.2.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
                        - 11.1.2.2.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US\$ Million)
                          - 11.1.2.2.4.1 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
                            - 11.1.2.2.4.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
                            - 11.1.2.2.4.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
                            - 11.1.2.2.4.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
                          - 11.1.2.2.5 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
                          - 11.1.2.2.6 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
                        - 11.1.2.3 India Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
                          - 11.1.2.3.1 Overview
                            - 11.1.2.3.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
                              - 11.1.2.3.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
                                - 11.1.2.3.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US\$ Million)
                                  - 11.1.2.3.4.1 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
                                    - 11.1.2.3.4.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
                                    - 11.1.2.3.4.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
                                    - 11.1.2.3.4.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
                                  - 11.1.2.3.5 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
                                  - 11.1.2.3.6 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
                                - 11.1.2.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1.2.4.1 Overview
- 11.1.2.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.1.2.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
- 11.1.2.4.4 South Korea: Glycomic Therapeutics Market, by Structures, 2019-2028 (US\$ Million)
  - 11.1.2.4.4.1 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
  - 11.1.2.4.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
  - 11.1.2.4.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
  - 11.1.2.4.4.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
- 11.1.2.4.5 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
- 11.1.2.4.6 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
- 11.1.2.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
  - 11.1.2.5.1 Overview
  - 11.1.2.5.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US\$ Million)
  - 11.1.2.5.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
  - 11.1.2.5.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US\$ Million)
    - 11.1.2.5.4.1 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
    - 11.1.2.5.4.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
    - 11.1.2.5.4.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
    - 11.1.2.5.4.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
  - 11.1.2.5.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
  - 11.1.2.5.6 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
- 11.1.2.6 Rest of Asia Pacific: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.2.6.1 Overview
  - 11.1.2.6.2 Rest of Asia Pacific: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
  - 11.1.2.6.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US\$ Million)
  - 11.1.2.6.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019-2028 (US\$ Million)
    - 11.1.2.6.4.1 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US\$ Million)
    - 11.1.2.6.4.2 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US\$ Million)
    - 11.1.2.6.4.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US\$ Million)
    - 11.1.2.6.4.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US\$ Million)
  - 11.1.2.6.5 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US\$ Million)
  - 11.1.2.6.6 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US\$ Million)
- 12. Glycomic Therapeutics Market -Industry Landscape
  - 12.1 Overview
  - 12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
  - 12.3 Organic Developments
    - 12.3.1 Overview
  - 12.4 Inorganic Developments
    - 12.4.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 13. Company Profiles
  - 13.1 BioMarin Pharmaceutical Inc.
    - 13.1.1 Key Facts
    - 13.1.2 Business Description
    - 13.1.3 Products and Services
    - 13.1.4 Financial Overview
    - 13.1.5 SWOT Analysis
    - 13.1.6 Key Developments
  - 13.2 Genzyme Corporation (Sanofi)
    - 13.2.1 Key Facts
    - 13.2.2 Business Description
    - 13.2.3 Products and Services
    - 13.2.4 Financial Overview
    - 13.2.5 SWOT Analysis
    - 13.2.6 Key Developments
  - 13.3 Bayer AG
    - 13.3.1 Key Facts
    - 13.3.2 Business Description
    - 13.3.3 Products and Services
    - 13.3.4 Financial Overview
    - 13.3.5 SWOT Analysis
    - 13.3.6 Key Developments
  - 13.4 GlaxoSmithKline plc.
    - 13.4.1 Key Facts
    - 13.4.2 Business Description
    - 13.4.3 Products and Services
    - 13.4.4 Financial Overview
    - 13.4.5 SWOT Analysis
    - 13.4.6 Key Developments
  - 13.5 F. Hoffmann-La Roche Ltd
    - 13.5.1 Key Facts
    - 13.5.2 Business Description
    - 13.5.3 Products and Services
    - 13.5.4 Financial Overview
    - 13.5.5 SWOT Analysis
    - 13.5.6 Key Developments
- 14. Appendix
  - 14.1 About The Insight Partners
  - 14.2 Glossary of Terms in Glycomic Therapeutics Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Asia Pacific Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 210 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)


**ORDER FORM:**

|                |         |       |
|----------------|---------|-------|
| Select license | License | Price |
|----------------|---------|-------|

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)




|                   |
|-------------------|
| Single User Price |
|-------------------|

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)






|            |
|------------|
| Site Price |
|------------|












**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)





**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)


**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)







**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.  
☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |   |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2025-05-07"/> |
|               |                      | Signature                     | <input type="text"/>                    |